Meropenem Can Be Safely Administered to Penicillin-Allergic Patients Without Prior Testing
In patients with a documented IgE-mediated penicillin allergy, meropenem can be administered without skin testing or additional precautions in most cases, as cross-reactivity is extremely low (0.3-0.9%). 1
Key Recommendation
The 2022 AAAAI/ACAAI Drug Allergy Practice Parameter provides a conditional recommendation with moderate certainty that carbapenems (including meropenem) may be given to patients with penicillin or cephalosporin allergy histories without testing or additional precautions. 1
Evidence Supporting Safety
The guideline evidence is compelling:
- Cross-reactivity rate: 0.87% (95% CI: 0.32%-2.32%) across 1,127 patients in meta-analysis 1
- Among 295 patients with positive penicillin skin tests, only 1 patient (0.3%) had a potentially IgE-mediated reaction to carbapenems 1
- A prospective study of 211 patients with skin test-confirmed penicillin allergy showed 100% tolerated carbapenems 1
Multiple research studies corroborate these findings, with cross-reactivity rates consistently under 1% 2, 3, 4.
Important Exceptions and Precautions
Do NOT give meropenem without allergy evaluation if:
- History of severe delayed cutaneous reactions (Stevens-Johnson syndrome, TEN, DRESS) 1
- History of organ-involved reactions 1
The FDA label warns that individuals with penicillin hypersensitivity history "have experienced severe hypersensitivity reactions when treated with another β-lactam" and recommends inquiring about previous reactions before initiating therapy 5. However, this generic warning predates the robust clinical evidence showing minimal cross-reactivity.
When to Consider Graded Challenge
While not required, a graded drug challenge may be preferred in: 1
- Patients with multiple drug allergies
- Patients with significant anxiety about the allergy
- Patients with severe anaphylaxis history to penicillin (though evidence still supports safety)
Clinical Algorithm
For immediate-type penicillin allergy (urticaria, angioedema, anaphylaxis):
- Verify the allergy is NOT a severe delayed reaction (SJS/TEN/DRESS)
- Administer meropenem directly without skin testing
- Monitor as you would any first dose of antibiotic
For severe delayed-type reactions:
- Avoid meropenem
- Seek allergy consultation
- Consider alternative non-β-lactam antibiotics
Common Pitfalls to Avoid
- Don't unnecessarily avoid carbapenems in penicillin-allergic patients—this leads to inferior antibiotic choices and contributes to resistance 6
- Don't confuse immediate and delayed reactions—only severe delayed cutaneous/organ reactions are contraindications
- Don't perform unnecessary skin testing—the evidence shows it adds no value for carbapenems in penicillin allergy 1
Bedside Safety Data
Recent real-world evidence from 182 hospitalized patients with penicillin allergy labels who received meropenem after bedside assessment showed 96.4% tolerance, with only 2 patients experiencing non-severe cutaneous reactions that resolved with treatment 7. This supports the safety of direct administration in clinical practice.
The practice of routinely avoiding meropenem in penicillin-allergic patients should be abandoned, as it leads to suboptimal antibiotic stewardship without meaningful safety benefit. 1, 4